期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 7, 期 9, 页码 508-519出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2010.116
关键词
-
类别
资金
- Breakthrough Breast Cancer
- Cancer Research UK
Drugs that inhibit the enzyme poly(ADP-ribose) polymerase (PARP) are showing considerable promise for the treatment of cancers that have mutations in the BRCA1 or BRCA2 tumor suppressors. This therapeutic approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in these tumors. High-grade ovarian cancers have a generally poor prognosis, and accumulating evidence suggests that mutations in BRCA1 or BRCA2, or silencing of BRCA1 by promoter methylation, may be common in this disease. Here, we consider how the potential benefit of PARP inhibitors might be maximized in ovarian cancer. We suggest that it will be crucial to explore novel therapeutic trial strategies and drug combinations, and incorporate robust biomarkers predictive of response if these drugs are to reach their full potential.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据